Top

Published in:

Open Access 12-12-2022 | Hyperkalemia | Review

Hyperkalemia: Prevalence, Predictors and Emerging Treatments

Authors: Natasha L. Larivée, Jacob B. Michaud, Keigan M. More, Jo-Anne Wilson, Karthik K. Tennankore

Published in: Cardiology and Therapy | Issue 1/2023

Abstract

It is well established that an elevated potassium level (hyperkalemia) is associated with a risk of adverse events including morbidity, mortality and healthcare system cost. Hyperkalemia is commonly encountered in many chronic conditions including kidney disease, diabetes and heart failure. Furthermore, hyperkalemia may result from the use of renin-angiotensin-aldosterone system inhibitors (RAASi), which are disease-modifying treatments for these conditions. Therefore, balancing the benefits of optimizing treatment with RAASi while mitigating hyperkalemia is crucial to ensure patients are optimally treated. In this review, we will briefly discuss the definition, causes, epidemiology and consequences of hyperkalemia. The majority of the review will be focused on management of hyperkalemia in the acute and chronic setting, emphasizing contemporary approaches and evolving data on the relevance of dietary restriction and the use of novel potassium binders.

Kanda E, Kashihara N, Kohsaka S, Okami S, Yajima T. Clinical and economic burden of hyperkalemia: a nationwide hospital-based cohort study in Japan. Kidney Med Nov-Dec. 2020;2(6):742-752.e1. https://doi.org/10.1016/j.xkme.2020.09.003.CrossRef

Hougen I, Leon SJ, Whitlock R, et al. Hyperkalemia and its association with mortality, cardiovascular events, hospitalizations, and intensive care unit admissions in a population-based retrospective cohort. Kidney Int Rep. 2021;6(5):1309–16. https://doi.org/10.1016/j.ekir.2021.02.038.CrossRefPubMedPubMedCentral

Fitch K, Woolley JM, Engel T, Blumen H. The clinical and economic burden of hyperkalemia on medicare and commercial payers. Am Health Drug Benefits. 2017;10(4):202–10.PubMedPubMedCentral

Kovesdy CP, Matsushita K, Sang Y, et al. Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis. Eur Heart J. 2018;39(17):1535–42. https://doi.org/10.1093/eurheartj/ehy100.CrossRefPubMedPubMedCentral

Collins AJ, Pitt B, Reaven N, et al. Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and/or diabetes. Am J Nephrol. 2017;46(3):213–21. https://doi.org/10.1159/000479802.CrossRefPubMed

Trevisan M, de Deco P, Xu H, et al. Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists. Eur J Heart Fail. 2018;20(8):1217–26. https://doi.org/10.1002/ejhf.1199.CrossRefPubMed

Clase CM, Carrero JJ, Ellison DH, et al. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2020;97(1):42–61. https://doi.org/10.1016/j.kint.2019.09.018.CrossRefPubMed

Einhorn LM, Zhan M, Hsu VD, et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med. 2009;169(12):1156–62. https://doi.org/10.1001/archinternmed.2009.132.CrossRefPubMedPubMedCentral

10.

Palmer BF, Carrero JJ, Clegg DJ, et al. Clinical Management of Hyperkalemia. Mayo Clin Proc. 2021;96(3):744–62. https://doi.org/10.1016/j.mayocp.2020.06.014.CrossRefPubMed

11.

Morales E, Cravedi P, Manrique J. Management of chronic hyperkalemia in patients with chronic kidney disease: an old problem with news options. Front Med (Lausanne). 2021;8: 653634. https://doi.org/10.3389/fmed.2021.653634.CrossRefPubMed

12.

Weinstein J, Girard L-P, Lepage S, McKelvie RS, Tennankore K. Prevention and management of hyperkalemia in patients treated with renin–angiotensin–aldosterone system inhibitors. Can Med Assoc J. 2021;193(48):E1836–41. https://doi.org/10.1503/cmaj.210831.CrossRef

13.

Agarwal R, Afzalpurkar R, Fordtran JS. Pathophysiology of potassium absorption and secretion by the human intestine. Gastroenterology. 1994;107(2):548–71. https://doi.org/10.1016/0016-5085(94)90184-8.CrossRefPubMed

14.

Kononowa N, Dickenmann MJ, Kim MJ. Severe hyperkalemia following colon diversion surgery in a patient undergoing chronic hemodialysis: a case report. J Med Case Rep. 2013;7:207. https://doi.org/10.1186/1752-1947-7-207.CrossRefPubMedPubMedCentral

15.

Saleh-Anaraki K, Jain A, Wilcox CS, Pourafshar N. Pseudohyperkalemia: three cases and a review of literature. Am J Med. 2022;135(7):e150–4. https://doi.org/10.1016/j.amjmed.2022.01.036.CrossRefPubMed

16.

Humphrey T, Davids MR, Chothia MY, Pecoits-Filho R, Pollock C, James G. How common is hyperkalaemia? A systematic review and meta-analysis of the prevalence and incidence of hyperkalaemia reported in observational studies. Clin Kidney J. 2022;15(4):727–37. https://doi.org/10.1093/ckj/sfab243.CrossRefPubMed

17.

Young JB, Dunlap ME, Pfeffer MA, et al. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation. 2004;110(17):2618–26. https://doi.org/10.1161/01.Cir.0000146819.43235.A9.CrossRefPubMed

18.

Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293–302. https://doi.org/10.1056/nejm199108013250501.CrossRefPubMed

19.

Miao Y, Dobre D, Heerspink HJ, et al. Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. Diabetologia. 2011;54(1):44–50. https://doi.org/10.1007/s00125-010-1922-6.CrossRefPubMed

20.

Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851–60. https://doi.org/10.1056/NEJMoa011303.CrossRefPubMed

21.

Hunter RW, Bailey MA. Hyperkalemia: pathophysiology, risk factors and consequences. Nephrol Dial Transplant. 2019;34(Suppl 3):iii2–11. https://doi.org/10.1093/ndt/gfz206.CrossRefPubMedPubMedCentral

22.

Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369(20):1892–903. https://doi.org/10.1056/NEJMoa1303154.CrossRefPubMed

23.

Wetmore JB, Yan H, Horne L, Peng Y, Gilbertson DT. Risk of hyperkalemia from renin-angiotensin-aldosterone system inhibitors and factors associated with treatment discontinuities in a real-world population. Nephrol Dial Transplant. 2021;36(5):826–39. https://doi.org/10.1093/ndt/gfz263.CrossRefPubMed

24.

Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351(6):543–51. https://doi.org/10.1056/NEJMoa040135.CrossRefPubMed

25.

Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med. 1999;341(10):709–17. https://doi.org/10.1056/nejm199909023411001.CrossRefPubMed

26.

Craft J. Eplerenone (Inspra), a new aldosterone antagonist for the treatment of systemic hypertension and heart failure. Proc (Bayl Univ Med Cent). 2004;17(2):217–20. https://doi.org/10.1080/08998280.2004.11927973.CrossRefPubMed

27.

White WB, Carr AA, Krause S, Jordan R, Roniker B, Oigman W. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am J Cardiol. 2003;92(1):38–42. https://doi.org/10.1016/s0002-9149(03)00461-2.CrossRefPubMed

28.

Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309–21. https://doi.org/10.1056/NEJMoa030207.CrossRefPubMed

29.

Agarwal R, Joseph A, Anker SD, et al. Hyperkalemia risk with finerenone: results from the FIDELIO-DKD Trial. J Am Soc Nephrol. 2022;33(1):225–37. https://doi.org/10.1681/asn.2021070942.CrossRefPubMedPubMedCentral

30.

Karaboyas A, Zee J, Brunelli SM, et al. Dialysate potassium, serum potassium, mortality, and arrhythmia events in hemodialysis: results from the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis. 2017;69(2):266–77. https://doi.org/10.1053/j.ajkd.2016.09.015.CrossRefPubMed

31.

Brunelli SM, Du Mond C, Oestreicher N, Rakov V, Spiegel DM. Serum potassium and short-term clinical outcomes among hemodialysis patients: impact of the long interdialytic interval. Am J Kidney Dis. 2017;70(1):21–9. https://doi.org/10.1053/j.ajkd.2016.10.024.CrossRefPubMed

32.

Viera AJ, Wouk N. Potassium disorders: hypokalemia and hyperkalemia. Am Fam Physician. 2015;92(6):487–95.PubMed

33.

Te Dorsthorst RPM, Hendrikse J, Vervoorn MT, van Weperen VYH, van der Heyden MAG. Review of case reports on hyperkalemia induced by dietary intake: not restricted to chronic kidney disease patients. Eur J Clin Nutr. 2019;73(1):38–45. https://doi.org/10.1038/s41430-018-0154-6.CrossRef

34.

Mu F, Betts KA, Woolley JM, et al. Prevalence and economic burden of hyperkalemia in the United States Medicare population. Curr Med Res Opin. 2020;36(8):1333–41. https://doi.org/10.1080/03007995.2020.1775072.CrossRefPubMed

35.

Betts KA, Woolley JM, Mu F, Xiang C, Tang W, Wu EQ. The cost of hyperkalemia in the United States. Kidney Int Rep. 2018;3(2):385–93. https://doi.org/10.1016/j.ekir.2017.11.003.CrossRefPubMed

36.

Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care. 2015;21(11 Suppl):S212–20.PubMed

37.

Fu EL, Evans M, Clase CM, et al. Stopping renin-angiotensin system inhibitors in patients with advanced CKD and risk of adverse outcomes: a nationwide study. J Am Soc Nephrol. 2021;32(2):424–35. https://doi.org/10.1681/asn.2020050682.CrossRefPubMed

38.

Walther CP, Winkelmayer WC, Richardson PA, Virani SS, Navaneethan SD. Renin-angiotensin system blocker discontinuation and adverse outcomes in chronic kidney disease. Nephrol Dial Transplant. 2021;36(10):1893–9. https://doi.org/10.1093/ndt/gfaa300.CrossRefPubMed

39.

Beusekamp JC, Tromp J, Cleland JGF, et al. Hyperkalemia and treatment with RAAS inhibitors during acute heart failure hospitalizations and their association with mortality. JACC Heart Fail. 2019;7(11):970–9. https://doi.org/10.1016/j.jchf.2019.07.010.CrossRefPubMed

40.

Adelborg K, Nicolaisen SK, Hasvold P, Palaka E, Pedersen L, Thomsen RW. Predictors for repeated hyperkalemia and potassium trajectories in high-risk patients—a population-based cohort study. PLoS ONE. 2019;14(6): e0218739. https://doi.org/10.1371/journal.pone.0218739.CrossRefPubMedPubMedCentral

41.

Sriperumbuduri S, McArthur E, Hundemer GL, et al. Initial and recurrent hyperkalemia events in patients with CKD in Older adults: a population-based cohort study. Can J Kidney Health Dis. 2021;8:20543581211017410. https://doi.org/10.1177/20543581211017408.CrossRefPubMedPubMedCentral

42.

Silva-Cardoso J, Brito D, Frazão JM, et al. Management of RAASi-associated hyperkalemia in patients with cardiovascular disease. Heart Fail Rev. 2021;26(4):891–6. https://doi.org/10.1007/s10741-020-10069-3.CrossRefPubMedPubMedCentral

43.

Group KDIGOW. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Off J Int Soc Nephrol. 2013;3(1):1–150.

44.

Allon M, Copkney C. Albuterol and insulin for treatment of hyperkalemia in hemodialysis patients. Kidney Int. 1990;38(5):869–72. https://doi.org/10.1038/ki.1990.284.CrossRefPubMed

45.

Apel J, Reutrakul S, Baldwin D. Hypoglycemia in the treatment of hyperkalemia with insulin in patients with end-stage renal disease. Clin Kidney J. 2014;7(3):248–50. https://doi.org/10.1093/ckj/sfu026.CrossRefPubMedPubMedCentral

46.

Chothia MY, Humphrey T, Schoonees A, Chikte UME, Davids MR. Hypoglycaemia due to insulin therapy for the management of hyperkalaemia in hospitalised adults: a scoping review. PLoS ONE. 2022;17(5): e0268395. https://doi.org/10.1371/journal.pone.0268395.CrossRefPubMedPubMedCentral

47.

Liou HH, Chiang SS, Wu SC, Yang WC, Huang TP. Intravenous infusion or nebulization of salbutamol for treatment of hyperkalemia in patients with chronic renal failure. Zhonghua Yi Xue Za Zhi (Taipei). 1994;53(5):276–81.PubMed

48.

Blumberg A, Weidmann P, Ferrari P. Effect of prolonged bicarbonate administration on plasma potassium in terminal renal failure. Kidney Int. 1992;41(2):369–74. https://doi.org/10.1038/ki.1992.51.CrossRefPubMed

49.

Wong SWS, Zhang G, Norman P, Welihinda H, Wijeratne DT. Polysulfonate resins in hyperkalemia: a systematic review. Can J Kidney Health Dis. 2020;7:2054358120965838. https://doi.org/10.1177/2054358120965838.CrossRefPubMedPubMedCentral

50.

Kovesdy CP. Management of hyperkalaemia in chronic kidney disease. Nat Rev Nephrol. 2014;10(11):653–62. https://doi.org/10.1038/nrneph.2014.168.CrossRefPubMed

51.

Simon LV, Hashmi MF, Farrell MW. Hyperkalemia. StatPearls Publishing LLC; 2022.

52.

Clegg DJ, Headley SA, Germain MJ. Impact of dietary potassium restrictions in CKD on clinical outcomes: benefits of a plant-based diet. Kidney Med. 2020;2(4):476–87. https://doi.org/10.1016/j.xkme.2020.04.007.CrossRefPubMedPubMedCentral

53.

Cupisti A, Kovesdy CP, D’Alessandro C, Kalantar-Zadeh K. Dietary approach to recurrent or chronic hyperkalaemia in patients with decreased kidney function. Nutrients. 2018. https://doi.org/10.3390/nu10030261.CrossRefPubMedPubMedCentral

54.

Levey AS, Rocco MV, Anderson S, et al. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(5 SUPPL. 1):i-S290.

55.

Levin A, Stevens PE, Bilous RW, et al. Kidney disease: improving global outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1–150.

56.

Bernier-Jean A, Wong G, Saglimbene V, et al. Dietary potassium intake and all-cause mortality in adults treated with hemodialysis. Clin J Am Soc Nephrol. 2021;16(12):1851–61. https://doi.org/10.2215/cjn.08360621.CrossRefPubMedPubMedCentral

57.

Narasaki Y, Okuda Y, Kalantar SS, et al. Dietary potassium intake and mortality in a prospective hemodialysis cohort. J Ren Nutr. 2021;31(4):411–20. https://doi.org/10.1053/j.jrn.2020.05.008.CrossRefPubMed

58.

Chiavaroli L, Viguiliouk E, Nishi SK, et al. DASH dietary pattern and cardiometabolic outcomes: an umbrella review of systematic reviews and meta-analyses. Nutrients. 2019. https://doi.org/10.3390/nu11020338.CrossRefPubMedPubMedCentral

59.

Institutet K, AstraZeneca. Healthy Diet Rich in Potassium to Chronic Kidney Disease With Sodium Zirconium Cyclosilicate: A Feasibility Study. https://ClinicalTrials.gov/show/NCT04207203; 2020.

60.

St-Jules DE, Fouque D. Etiology-based dietary approach for managing hyperkalemia in people with chronic kidney disease. Nutr Rev. 2022. https://doi.org/10.1093/nutrit/nuac026.CrossRefPubMed

61.

Chauveau P, Aparicio M, Bellizzi V, et al. Mediterranean diet as the diet of choice for patients with chronic kidney disease. Nephrol Dial Transplant. 2018;33(5):725–35. https://doi.org/10.1093/ndt/gfx085.CrossRefPubMed

62.

Smyth A, Griffin M, Yusuf S, et al. Diet and major renal outcomes: a prospective cohort study. The NIH-AARP diet and health study. J Ren Nutr. 2016;26(5):288–98. https://doi.org/10.1053/j.jrn.2016.01.016.CrossRefPubMed

63.

Joshi S, McMacken M, Kalantar-Zadeh K. Plant-based diets for kidney disease: a guide for clinicians. Am J Kidney Dis. 2021;77(2):287–96. https://doi.org/10.1053/j.ajkd.2020.10.003.CrossRefPubMed

64.

Dietary Potassium Liberalization in Pre-Dialysis Patients (DK-LIB). ClinicalTrialsgov Identifier: NCT05090865.

65.

Babich JS, Kalantar-Zadeh K, Joshi S. Taking the kale out of hyperkalemia: plant foods and serum potassium in patients with kidney disease. J Ren Nutr. 2022. https://doi.org/10.1053/j.jrn.2022.01.013.CrossRefPubMed

66.

Naismith DJ, Braschi A. An investigation into the bioaccessibility of potassium in unprocessed fruits and vegetables. Int J Food Sci Nutr. 2008;59(5):438–50. https://doi.org/10.1080/09637480701690519.CrossRefPubMed

67.

Cook EE, Davis J, Israni R, et al. Prevalence of metabolic acidosis among patients with chronic kidney disease and hyperkalemia. Adv Ther. 2021;38(10):5238–52. https://doi.org/10.1007/s12325-021-01886-5.CrossRefPubMedPubMedCentral

68.

Dunn JD, Benton WW, Orozco-Torrentera E, Adamson RT. The burden of hyperkalemia in patients with cardiovascular and renal disease. Am J Manag Care. 2015;21(15 Suppl):s307–15.PubMed

69.

Dobre M, Yang W, Pan Q, et al. Persistent high serum bicarbonate and the risk of heart failure in patients with chronic kidney disease (CKD): a report from the Chronic Renal Insufficiency Cohort (CRIC) study. J Am Heart Assoc. 2015. https://doi.org/10.1161/jaha.114.001599.CrossRefPubMedPubMedCentral

70.

Melamed ML, Horwitz EJ, Dobre MA, et al. Effects of sodium bicarbonate in CKD stages 3 and 4: a randomized, placebo-controlled, multicenter clinical trial. Am J Kidney Dis. 2020;75(2):225–34. https://doi.org/10.1053/j.ajkd.2019.07.016.CrossRefPubMed

71.

Abramowitz MK, Melamed ML, Bauer C, Raff AC, Hostetter TH. Effects of oral sodium bicarbonate in patients with CKD. Clin J Am Soc Nephrol. 2013;8(5):714–20. https://doi.org/10.2215/cjn.08340812.CrossRefPubMedPubMedCentral

72.

de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol. 2009;20(9):2075–84. https://doi.org/10.1681/asn.2008111205.CrossRefPubMedPubMedCentral

73.

Ben Salem C, Badreddine A, Fathallah N, Slim R, Hmouda H. Drug-induced hyperkalemia. Drug Saf. 2014;37(9):677–92. https://doi.org/10.1007/s40264-014-0196-1.CrossRefPubMed

74.

Rimmer JM, Horn JF, Gennari FJ. Hyperkalemia as a complication of drug therapy. Arch Intern Med. 1987;147(5):867–9. https://doi.org/10.1001/archinte.1987.00370050063011.CrossRefPubMed

75.

Perazella MA. Drug-induced hyperkalemia: old culprits and new offenders. The Am J Med. 2000;109(4):307–14. https://doi.org/10.1016/S0002-9343(00)00496-4.CrossRefPubMed

76.

Sica DA. Diuretic-related side effects: development and treatment. J Clin Hypertens (Greenwich). 2004;6(9):532–40. https://doi.org/10.1111/j.1524-6175.2004.03789.x.CrossRefPubMed

77.

Agarwal R, Sinha AD, Cramer AE, et al. Chlorthalidone for hypertension in advanced chronic kidney disease. N Engl J Med. 2021;385(27):2507–19. https://doi.org/10.1056/NEJMoa2110730.CrossRefPubMedPubMedCentral

78.

Rossing P, Filippatos G, Agarwal R, et al. Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy. Kidney Int Rep. 2022;7(1):36–45. https://doi.org/10.1016/j.ekir.2021.10.008.CrossRefPubMed

79.

Neuen BL, Oshima M, Agarwal R, et al. Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials. Circulation. 2022;145(19):1460–70. https://doi.org/10.1161/circulationaha.121.057736.CrossRefPubMed

80.

Lo KB, Gul F, Ram P, et al. The effects of SGLT2 inhibitors on cardiovascular and renal outcomes in diabetic patients: a systematic review and meta-analysis. Cardiorenal Med. 2020;10(1):1–10. https://doi.org/10.1159/000503919.CrossRefPubMed

81.

Bailey CJ, Day C, Bellary S. Renal protection with SGLT2 inhibitors: effects in acute and chronic kidney disease. Curr Diab Rep. 2022;22(1):39–52. https://doi.org/10.1007/s11892-021-01442-z.CrossRefPubMedPubMedCentral

82.

Herrington W, Wanner C, Green JB. Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial. Nephrol Dial Transplant. 2022;37(7):1317–29. https://doi.org/10.1093/ndt/gfac040.CrossRef

83.

Evans BM, Milne MD, Jones NC, Yellowlees H. Ion-exchange resins in the treatment of anuria. Lancet. 1953;265(6790):791–5. https://doi.org/10.1016/s0140-6736(53)90465-6.CrossRefPubMed

84.

Lepage L, Dufour AC, Doiron J, et al. Randomized clinical trial of sodium polystyrene sulfonate for the treatment of mild hyperkalemia in CKD. Clin J Am Soc Nephrol. 2015;10(12):2136–42. https://doi.org/10.2215/cjn.03640415.CrossRefPubMedPubMedCentral

85.

Fordjour KN, Walton T, Doran JJ. Management of hyperkalemia in hospitalized patients. Am J Med Sci. 2014;347(2):93–100. https://doi.org/10.1097/MAJ.0b013e318279b105.CrossRefPubMed

86.

Noel JA, Bota SE, Petrcich W, et al. Risk of hospitalization for serious adverse gastrointestinal events associated with sodium polystyrene sulfonate use in patients of advanced age. JAMA Intern Med. 2019;179(8):1025–33. https://doi.org/10.1001/jamainternmed.2019.0631.CrossRefPubMedPubMedCentral

87.

Watson MA, Baker TP, Nguyen A, et al. Association of prescription of oral sodium polystyrene sulfonate with sorbitol in an inpatient setting with colonic necrosis: a retrospective cohort study. Am J Kidney Dis. 2012;60(3):409–16. https://doi.org/10.1053/j.ajkd.2012.04.023.CrossRefPubMed

88.

Harel Z, Harel S, Shah PS, Wald R, Perl J, Bell CM. Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. Am J Med. 2013;126(3):264.e9-24. https://doi.org/10.1016/j.amjmed.2012.08.016.CrossRefPubMed

89.

Jadoul M, Karaboyas A, Goodkin DA, et al. Potassium-binding resins: associations with serum chemistries and interdialytic weight gain in hemodialysis patients. Am J Nephrol. 2014;39(3):252–9. https://doi.org/10.1159/000360094.CrossRefPubMed

90.

Nasir K, Ahmad A. Treatment of hyperkalemia in patients with chronic kidney disease: a comparison of calcium polystyrene sulphonate and sodium polystyrene sulphonate. J Ayub Med Coll Abbottabad. 2014;26(4):455–8.PubMed

91.

Nakayama Y, Ueda K, Yamagishi SI, et al. Compared effects of calcium and sodium polystyrene sulfonate on mineral and bone metabolism and volume overload in pre-dialysis patients with hyperkalemia. Clin Exp Nephrol. 2018;22(1):35–44. https://doi.org/10.1007/s10157-017-1412-y.CrossRefPubMed

92.

Wang J, Lv MM, Zach O, et al. Calcium-polystyrene sulfonate decreases inter-dialytic hyperkalemia in patients undergoing maintenance hemodialysis: a prospective, randomized, crossover study. Ther Apher Dial. 2018;22(6):609–16. https://doi.org/10.1111/1744-9987.12723.CrossRefPubMed

93.

Arroyo D, Panizo N, García de Vinuesa S, Goicoechea M, Verdalles U, Luño J. Hypercalcemia as a side effect of potassium binding agents. Nefrologia. 2012;32(5):655–8. https://doi.org/10.3265/Nefrologia.pre2012.Jun.11500.CrossRefPubMed

94.

Buraphat P, Niyomnaitham S, Pongpaibul A, Maneerattanaporn M. Calcium polystyrene sulfonate-induced gastrointestinal tract necrosis and perforation. Acta Gastroenterol Belg. 2019;82(4):542–3.PubMed

95.

Ribeiro H, Pereira E, Banhudo A. Colonic Necrosis Induced by Calcium Polystyrene Sulfonate. GE Port J Gastroenterol. 2018;25(4):205–7. https://doi.org/10.1159/000481288.CrossRefPubMed

96.

Castillo-Cejas MD, de-Torres-Ramírez I, Alonso-Cotoner C. Colonic necrosis due to calcium polystyrene sulfonate (Kalimate) not suspended in sorbitol. Rev Esp Enferm Dig. 2013;105(4):232–4. https://doi.org/10.4321/s1130-01082013000400010.CrossRefPubMed

97.

Rosano GMC, Tamargo J, Kjeldsen KP, et al. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eu Heart J Cardiovasc Pharmacother. 2018;4(3):180–8. https://doi.org/10.1093/ehjcvp/pvy015.CrossRef

98.

Pitt B, Bakris GL, Bushinsky DA, et al. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail. 2015;17(10):1057–65. https://doi.org/10.1002/ejhf.402.CrossRefPubMed

99.

Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015;372(3):211–21. https://doi.org/10.1056/NEJMoa1410853.CrossRefPubMed

100.

Agarwal R, Rossignol P, Romero A, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2019;394(10208):1540–50. https://doi.org/10.1016/s0140-6736(19)32135-x.CrossRefPubMed

101.

Packham DK, Rasmussen HS, Lavin PT, et al. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med. 2015;372(3):222–31. https://doi.org/10.1056/NEJMoa1411487.CrossRefPubMed

102.

Ash SR, Singh B, Lavin PT, Stavros F, Rasmussen HS. A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient. Kidney Int. 2015;88(2):404–11. https://doi.org/10.1038/ki.2014.382.CrossRefPubMedPubMedCentral

103.

Spinowitz BS, Fishbane S, Pergola PE, et al. Sodium zirconium cyclosilicate among individuals with hyperkalemia: a 12-month phase 3 study. Clin J Am Soc Nephrol. 2019;14(6):798–809. https://doi.org/10.2215/cjn.12651018.CrossRefPubMedPubMedCentral

104.

Butler J, Anker SD, Lund LH, et al. Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. Eur Heart J. 2022. https://doi.org/10.1093/eurheartj/ehac401.CrossRefPubMedPubMedCentral

105.

Bakris GL, Pitt B, Weir MR, et al. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA. 2015;314(2):151–61. https://doi.org/10.1001/jama.2015.7446.CrossRefPubMed

106.

Roger SD, Spinowitz BS, Lerma EV, et al. Efficacy and safety of sodium zirconium cyclosilicate for treatment of hyperkalemia: an 11-month open-label extension of HARMONIZE. Am J Nephrol. 2019;50(6):473–80. https://doi.org/10.1159/000504078.CrossRefPubMed

107.

Kashihara N, Nishio T, Osonoi T, et al. Correction of serum potassium with sodium zirconium cyclosilicate in Japanese patients with hyperkalemia: a randomized, dose-response, phase 2/3 study. Clin Exp Nephrol. 2020;24(12):1144–53. https://doi.org/10.1007/s10157-020-01937-1.CrossRefPubMedPubMedCentral

108.

Kosiborod M, Rasmussen HS, Lavin P, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA. 2014;312(21):2223–33. https://doi.org/10.1001/jama.2014.15688.CrossRefPubMed

109.

CADTH Common Drug Reviews. CADTH Canadian Drug Expert Committee Recommendation: Sodium Zirconium Cyclosilicate (Lokelma—Astrazeneca Canada Inc): Indication: Hyperkalemia. Canadian Agency for Drugs and Technologies in Health Copyright © 2020 Canadian Agency for Drugs and Technologies in Health.; 2020.

110.

Fishbane S, Ford M, Fukagawa M, et al. A phase 3b, randomized, double-blind, placebo-controlled study of sodium zirconium cyclosilicate for reducing the incidence of predialysis hyperkalemia. J Am Soc Nephrol. 2019;30(9):1723–33. https://doi.org/10.1681/asn.2019050450.CrossRefPubMedPubMedCentral

111.

Bushinsky DA, Rossignol P, Spiegel DM, et al. Patiromer decreases serum potassium and phosphate levels in patients on hemodialysis. Am J Nephrol. 2016;44(5):404–10. https://doi.org/10.1159/000451067.CrossRefPubMed

112.

Rafique Z, Liu M, Staggers KA, Minard CG, Peacock WF. Patiromer for treatment of hyperkalemia in the emergency department: a pilot study. Acad Emerg Med. 2020;27(1):54–60. https://doi.org/10.1111/acem.13868.CrossRefPubMed

113.

Peacock WF, Rafique Z, Vishnevskiy K, et al. Emergency potassium normalization treatment including sodium zirconium cyclosilicate: a phase II, randomized, double-blind, placebo-controlled study (ENERGIZE). Acad Emerg Med. 2020;27(6):475–86. https://doi.org/10.1111/acem.13954.CrossRefPubMedPubMedCentral

114.

Natale P, Palmer SC, Ruospo M, Saglimbene VM, Strippoli GF. Potassium binders for chronic hyperkalaemia in people with chronic kidney disease. Cochrane Database Syst Rev. 2020;6(6):Cd013165. https://doi.org/10.1002/14651858.CD013165.pub2.CrossRefPubMed

115.

Butler J, Anker SD, Siddiqi TJ, et al. Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial. Eur J Heart Fail. 2022;24(1):230–8. https://doi.org/10.1002/ejhf.2386.CrossRefPubMed

116.

Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes). https://ClinicalTrials.gov/show/NCT04847232.

117.

Murphy D, Ster IC, Kaski JC, Anderson L, Banerjee D. The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K(+)-binder Lokelma for maximisation of RAAS inhibition in CKD patients with heart failure. BMC Nephrol. 2021;22(1):254. https://doi.org/10.1186/s12882-021-02439-2.CrossRefPubMedPubMedCentral

118.

Hospital OU. Effects of patiromer on pharmacokinetics of immunosuppresive drugs in renal transplant recipients. https://ClinicalTrials.gov/show/NCT05029310; 2021.

119.

AstraZeneca. An open-label study to assess safety and efficacy of szc in paediatric patients with hyperkalaemia. https://ClinicalTrials.gov/show/NCT03813407; 2019.

120.

AstraZeneca, Parexel. Study to assess the effect of sodium zirconium cyclosilicate on the pharmacokinetics of tacrolimus and cyclosporin in healthy subjects. https://ClinicalTrials.gov/show/NCT04788641; 2021.

121.

Vifor Pharma I, Pharma V. Pharmacodynamic & safety of Patiromer in children & adolescents (2-<18 Yrs) with chronic kidney disease and hyperkalemia. https://ClinicalTrials.gov/show/NCT03087058; 2017.

122.

Institute TR, University WMCoC. Pharmacokinetic study of tacrolimus and mycophenolate mofetil in kidney transplant recipients with hyperkalemia receiving patiromer. https://ClinicalTrials.gov/show/NCT03229265; 2017.

123.

Wadhwa N, Cancer NHdbaNY, Specialists B. Evaluation of increased fruits and vegetables consumption in chronic kidney disease. https://ClinicalTrials.gov/show/NCT05050110; 2020.

124.

University D, Pharma V. Patiromer Efficacy to reduce episodic hyperkalemia in end stage renal disease patients. https://ClinicalTrials.gov/show/NCT03781089; 2019.

125.

AstraZeneca. Continuing sodium zirconium cyclosilicate (SZC) after discharge study. https://ClinicalTrials.gov/show/NCT05347693; 2022.

126.

Hospital GPPs. Sodium zirconium cyclosilicate lowers hyperkalemia after parathyroidectomy. https://ClinicalTrials.gov/show/NCT05382988; 2016.

127.

Research IIfM. Spironolactone in CKD enabled by chlorthalidone: PILOT. https://ClinicalTrials.gov/show/NCT05222191; 2022.

128.

Manitoba Uo, University D. Dietary Potassium Liberalization in Pre-Dialysis Patients. https://ClinicalTrials.gov/show/NCT05090865; 2022.

129.

KDIGO. Clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2020;98(4s):S1-s115. https://doi.org/10.1016/j.kint.2020.06.019.CrossRef

130.

Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200. https://doi.org/10.1093/eurheartj/ehw128.CrossRefPubMed

131.

Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):1810–52. https://doi.org/10.1161/CIR.0b013e31829e8807.CrossRefPubMed

132.

Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158(11):825–30. https://doi.org/10.7326/0003-4819-158-11-201306040-00007.CrossRefPubMed

133.

National Institute for Health and Care Excellence: Guidelines. Chronic kidney disease: assessment and management. National Institute for Health and Care Excellence (NICE). Copyright © NICE 2021.; 2021.

134.

sanofi-aventis Canada Inc. Prescribing Information: Kayexalate. Sodium Polystyrene Sulfonate. Cation - Exchange Resin. sanofi-aventis Canada Inc. https://products.sanofi.ca/en/kayexalate.pdf. Accessed 10 May 2022.

135.

Ltd. VFMCRP. Product Monograph: Veltassa. Patiromer Powder for Oral Suspension (Potassium Binder (ATC Code: V03AE09)). Vifor Fresenius Medical Care Renal Pharma Ltd. https://pdf.hres.ca/dpd_pm/00053458.PDF. Accessed 10 May 2022.

136.

Inc. AC. Product Monograph: Lokelma. Sodium zirconium cyclosilicate powder for oral suspension. (Potassium Binder (ATC Code V03AE10)). ZS Pharma, Inc. https://www.astrazeneca.ca/content/dam/az-ca/downloads/productinformation/lokelma-product-monograph-en.pdf. Accessed 10 May 2022.

137.

Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang IZ. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011;32(7):820–8. https://doi.org/10.1093/eurheartj/ehq502.CrossRefPubMedPubMedCentral

138.

Rossignol P, Williams B, Mayo MR, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure. Eur J Heart Fail. 2020;22(8):1462–71. https://doi.org/10.1002/ejhf.1860.CrossRefPubMed

139.

Agarwal R, Rossignol P, Budden J, et al. Patiromer and spironolactone in resistant hypertension and advanced CKD: analysis of the randomized AMBER trial. Kidney360. 2021;2(3):425–34. https://doi.org/10.34067/kid.0006782020.CrossRefPubMedPubMedCentral

140.

Anker SD, Kosiborod M, Zannad F, et al. Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. Eur J Heart Fail. 2015;17(10):1050–6. https://doi.org/10.1002/ejhf.300.CrossRefPubMed

141.

Kashihara N, Yamasaki Y, Osonoi T, et al. A phase 3 multicenter open-label maintenance study to investigate the long-term safety of sodium zirconium cyclosilicate in Japanese subjects with hyperkalemia. Clin Exp Nephrol. 2021;25(2):140–9. https://doi.org/10.1007/s10157-020-01972-y.CrossRefPubMed

Title: Hyperkalemia: Prevalence, Predictors and Emerging Treatments
Authors: Natasha L. Larivée
Jacob B. Michaud
Keigan M. More
Jo-Anne Wilson
Karthik K. Tennankore
Publication date: 12-12-2022
Publisher: Springer Healthcare
Keyword: Hyperkalemia
Published in: Cardiology and Therapy / Issue 1/2023
Print ISSN: 2193-8261
Electronic ISSN: 2193-6544
DOI: https://doi.org/10.1007/s40119-022-00289-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2023

Pulmonary Thromboembolism Developed During Hospitalization: A Nationwide Retrospective Observational Study Using Claims Data

Targeted Temperature Management in Cardiac Arrest

Detection and Diagnosis of Cardiac Amyloidosis in Egypt

The Use of Midodrine as an Adjunctive Therapy to Liberate Patients from Intravenous Vasopressors: A Systematic Review and Meta-analysis of Randomized Controlled Studies

Emerging PET Tracers in Cardiac Molecular Imaging

Effects of Melatonin on Cardiac Injury and Inflammatory Biomarkers in Patients Undergoing Coronary Artery Bypass Graft Surgery: a Meta-analysis

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage